ATC Group: N05BA02 Chlordiazepoxide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05BA02 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05B Anxiolytics
4 N05BA Benzodiazepine derivatives
5 N05BA02 Chlordiazepoxide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg
PAREN - Parenteral 50 mg

Active ingredients in N05BA02

Active Ingredient Description
Chlordiazepoxide

Chlordiazepoxide has anxiolytic and central muscle relaxant properties. It has little autonomic activity. Chlordiazepoxide acts as depressant of the central nervous system producing all levels of CNS depression, from mild sedation to hypnosis, to coma depending on the dose.

Related product monographs

Title Information Source Document Type  
LIBRIUM Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Estonia (EE)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.